Merck & Co., Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US58933Y1055
USD
100.89
-1.38 (-1.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Merck & Co., Inc. stock-summary
stock-summary
Merck & Co., Inc.
Pharmaceuticals & Biotechnology
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Company Coordinates stock-summary
Company Details
2000 Galloping Hill Rd , KENILWORTH NJ : 07033-1310
stock-summary
Tel: 1 908 7404000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 302 Schemes (30.89%)

Foreign Institutions

Held by 720 Foreign Institutions (18.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kenneth Frazier
Chairman of the Board, President, Chief Executive Officer
Mr. Leslie Brun
Lead Independent Director
Dr. Thomas Cech
Independent Director
Ms. Mary Coe
Independent Director
Ms. Pamela Craig
Independent Director
Mr. Thomas Glocer
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
15,800 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,428 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 298,483 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5.44%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

38.86%

stock-summary
Price to Book

6.09